As capital sources become more elusive, companies are increasingly exploring creative methods to structure transactions and it is more important than ever to find successful transaction structures that build value. This session will focus on unique financial structures that have been utilized to leverage industry and financing opportunities.
This panel will review the following:
Combined deferred mergers and product development licenses
Debt transactions
Equity lines
The use of business incubators
Moderator:
- Richard A. Kaufman, Partner, Foley & Lardner
Panelists:
- Mark Benedyk, Head of The Pfizer Incubator LLC
- Donna Tempel, Ph.D., President and CEO, Drais Pharmaceuticals
- Jack Lief, Co-Founder, Chairman, President & CEO, Arena Pharmaceuticals
- Michael White, Deal Team Leader, Silicon Valley Bank
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.